Adept Biopharmaceutical

Adept Biopharmaceutical and Technology, Ltd. (AdeptTx) is an innovative biotechnology company founded in 2021, with operations in Shenzhen, China, and the Greater Boston area. The company specializes in developing next-generation immuno-therapeutics for cancer, focusing on challenging targets such as G-protein coupled receptors (GPCRs). AdeptTx leverages its proprietary platforms to create a diverse pipeline of monoclonal antibodies, bispecific immune cell engagers, trispecific antibodies, and antibody-drug conjugates (ADCs). Its lead programs include AT-004, a potent A2aR antagonist antibody, and AT-001, an anti-PD-L1 ADC, both currently in pre-clinical development for solid tumors. The company aims to overcome tumor immune escape mechanisms by modulating the tumor microenvironment and enhancing anti-tumor immunity.